Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Quarterly results
Auditor change
Appointed director
Director comp.
Acq. announced
BioCardia, Inc. (BCDA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/11/2023 8-K Quarterly results
08/21/2023 8-K Shareholder Nominations Pursuant to Exchange Act Rule 14a-11  Interactive Data
08/09/2023 8-K Quarterly results
Docs: "BIOCARDIA REPORTS SECOND QUARTER 2023 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS Sunnyvale, Calif. – August 9, 2023 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the second quarter of 2023 and filed its quarterly report on Form 10-Q for the three and six months ended June 30, 2023 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session. “We have followed the recent recommendation from our Data Safety Monitoring Board to pause enrollment of new patients in our autologous cell ..."
07/24/2023 8-K Quarterly results
07/05/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BioCardia Completes Submission of CardiAMP Cell Therapy System in Heart Failure to Japan’s Pharmaceutical Medical Device Agency July 5, 2023 Sunnyvale, Calif. – BioCardia ® , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces it completed its submission of the CardiAMP Cell Therapy System to Japan’s Pharmaceutical and Medical Device Agency towards approval for the indication of ischemic heart failure with reduced ejection fraction . The formal consultation with PMDA to review the submission is anticipated in approximately three months and will be BioCardia’s third consultation with PMDA. “We believe there is high potential for approval of the CardiAMP Cell Therapy for Heart Failure in Japan ..."
06/30/2023 8-K Termination of a Material Definitive Agreement, Other Events  Interactive Data
06/08/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BioCardia Announces Helix™ Biotherapeutic Delivery Patent Issuance in Japan Sunnyvale, Calif. – BioCardia ® , Inc. [Nasdaq: BCDA], a company focused on cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases today announces that the Japan Patent Office has granted Patent No: JP7282649B2 titled “Radial and Transendocardial Delivery Catheter” with a patent term that will expire on September 30, 2034. This patent describes interventional biotherapeutic delivery catheters to deliver biologics to specific target sites from within the heart chamber. The allowed claims cover BioCardia’s helical needle tipped catheter technology platform in existing products and in future products in active development with enhanced features. “Our Helix™ minima..."
05/10/2023 8-K Quarterly results
Docs: "BIOCARDIA REPORTS FIRST QUARTER 2023 BUSINESS HIGHLIGHTS AND FINANCIAL RESULTS Sunnyvale, Calif. – May 10, 2023 - BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reports financial results for the first quarter of 2023 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2023 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session. “Our autologous and allogeneic cell therapy programs are advancing in the clinic, with three enabled by our Helix cardiac biotherapeutic delivery system..."
05/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BioCardia Announces US Patent on Bone Marrow Derived Neurokinin-1 Receptor Positive Mesenchymal Stem Cells for Therapeutic Applications SUNNYVALE, Calif. – – BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office has granted Patent Number 11,642,377: titled, “ Bone Marrow Derived Neurokinin-1 Receptor Positive Mesenchymal Stem Cells for Therapeutic Applications”, with a patent term that will expire in 2039. The patent specification details methods for selecting and expanding NK1R+ Mesenchymal Stem Cells and their use to treat a number of diseases. The first allowed claim protects using these cells to treat cardiovascular disease, pain, rheumatoid ..."
05/01/2023 8-K Quarterly results
04/28/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
04/04/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BioCardia Announces Issuance of Two Patents Related to Technology That Guides Interventional Therapies SUNNYVALE, Calif. – – BioCardia ® , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the issuance of two patent grants related to enabling technologies for delivery of its investigational autologous and allogeneic cell therapies. The United States Patent Office issued BioCardia Patent Number 11,716,859, entitled “Multi-Directional Steerable Catheter,” with a patent term that will expire in 2035. The patent claims a fundamental design for steerable introducer sheaths, such as those used for BioCardia’s autologous and allogeneic cell therapy procedures, and for transseptal procedures for th..."
03/29/2023 8-K Quarterly results
03/06/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
02/01/2023 8-K Quarterly results
12/22/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: " "
12/15/2022 8-K Asset disposition
Docs: " "
12/06/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
11/09/2022 8-K Quarterly results
10/03/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "BioCardia Presents Positive CardiAMP Cell Therapy Heart Failure Trial Two-Year Data at HFSA Annual Meeting Clinical Leadership and Management Call Scheduled for Wednesday, October 5, 2022, at 8:55am Eastern Time"
09/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "CardiAMP Cell Therapy Heart Failure Trial Two Year Roll In Cohort Data to be Presented at Heart Failure Society of America Annual Meeting"
08/31/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
08/24/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "BioCardia Enters Agreement with BlueRock Therapeutics to Provide Enabling Catheter Biotherapeutic Delivery Product Candidates for BlueRock’s Cell Therapy to Treat Heart Failure"
08/10/2022 8-K Quarterly results
08/01/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial SUNNYVALE, Calif. – August 1, 2022 – BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of Ottawa Heart Institute, the first Canadian clinical investigational site for the CardiAMP® Cell Therapy Heart Failure Trial. “The Ottawa Heart Institute is the first of four planned world-class Canadian clinical sites able to enroll patients in the CardiAMP Cell Therapy Heart Failure Trial.” Said Dr. Peter Altman, BioCardia CEO. “Our expectation is that each site will contribute six patients per year to the ongoing pivotal trial enrollment in the U.S. and facilitate completion of this important p..."
06/15/2022 8-K Quarterly results
06/10/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
04/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " ",
" "
04/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "INVESTOR CONTACT:"
03/29/2022 8-K Quarterly results
Docs: "BIOCARDIA REPORTS 2021 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS Sunnyvale, Calif. – March 29, 2022 - BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the year ended December 31, 2021 and filed its annual report on Form 10-K for the year ended December 31, 2021 with the Securities and Exchange Commission. The Company will also hold an update conference call at 4:30 PM ET, in which it will discuss business highlights. Following management’s formal remarks, there will be a question and answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10164538/f1ee9a93ce. Please note that registered participants w..."
03/22/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: " "
03/01/2022 8-K Quarterly results
02/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "BioCardia Announces Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy